Pediatrix Medical Group Stock Price Expected to Rise, Truist Financial Analyst Says

Investment firm lifts price target on healthcare company's shares

Apr. 13, 2026 at 5:27pm

Got story updates? Submit your updates here. ›

A high-contrast black and white close-up photograph of complex medical machinery and equipment, representing the advanced infrastructure supporting Pediatrix's specialized healthcare services.Specialized medical equipment and technology underpin Pediatrix's role as a leading provider of high-acuity pediatric and maternal-fetal care.Sunrise Today

Truist Financial analysts have raised their price target on shares of Pediatrix Medical Group (NYSE:MD) from $21.00 to $23.00 and maintained a 'hold' rating on the stock. The analysts cited the company's performance and outlook in a new research report.

Why it matters

Pediatrix Medical Group is a major provider of neonatal, maternal-fetal, and pediatric subspecialty care services across the United States. As a publicly traded company, analyst ratings and price targets can influence investor sentiment and the stock's trading price.

The details

In their report, the Truist Financial analysts noted that the new $23.00 price target represents a potential upside of 6.93% from the stock's previous closing price. Several other research firms have also recently weighed in on Pediatrix, with ratings ranging from 'hold' to 'strong buy'.

  • Truist Financial issued the updated price target and rating on April 13, 2026.

The players

Pediatrix Medical Group

A national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care, headquartered in Sunrise, Florida.

Truist Financial

An investment banking and financial services company that provides research coverage and ratings on Pediatrix Medical Group.

Got photos? Submit your photos here. ›

The takeaway

The updated price target from Truist Financial suggests analysts see potential upside in Pediatrix Medical Group's stock, though the 'hold' rating indicates the company's performance and outlook are viewed as relatively stable rather than highly bullish. Investors will likely monitor how the stock trades in the coming weeks and months based on this latest analyst coverage.